ID 900 - Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225)

PL: Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225)
EN: Lactobacillus johnsonii NCC 533 (La1) (Pasteur culture collection CNCM I-1225)
Pdf: Lactobacillus johnsonii NCC 533

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claims is “Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225)”, (hereafter L. johnsonii NCC 533 or L. johnsonii La1).
The identification/characterisation of the strain L. johnsonii NCC 533 has not been included in the studies provided but different studies on phenotypic and genotypic identification/characterisation can be found in the literature (Berger et al., 2007; Ventura et al., 2004). In addition, the genome sequence of L. johnsonii NCC 533 is publicly available at the NCBI database (accession NC_005362) (Pridmore et al., 2004). A culture collection number from the Collection Nationale de Cultures de Microorganismes (CNCM) was also provided. The strain Lactobacillus acidophilus La1 has been re-classified as L. johnsonii La1.
The Panel considers that the food constituent, Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225), which is the subject of the health claims, is sufficiently characterised.

2.2. Ochrona skóry przed uszkodzeniami wywołanymi promieniami ultrafioletowymi (UV) (ID 900)

The claimed effect is “skin health”. The Panel assumes that the target population is the general population.
In the context of the clarifications provided by Member States, the Panel assumes that the claimed effect refers to protection of the skin from UV-induced damage.
The Panel considers that protection of the skin from UV-induced damage is a beneficial physiological effect.

3.2. Ochrona skóry przed uszkodzeniami wywołanymi promieniami ultrafioletowymi (UV) (ID 900)

Among the references provided in relation to the claim were unpublished reports, meeting abstracts or posters, which were either not accessible to the Panel or did not contain sufficient information for a full scientific evaluation. One animal study on the development of atopic dermatitis did not address outcomes related to the claimed effect. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claim.
In a double-blind, randomised, placebo-controlled human intervention study (Peguet-Navarro et al., 2008), 54 healthy male volunteers (aged 20 to 40 years) received daily oral supplementation with either L. johnsonii La1 (1x1010 CFU, n=27) or placebo (maltodextrin, n=27) for 66 days. Suction blister roofs and skin biopsies were taken from the right and left buttocks of each volunteer at baseline, and the UV minimal erythemal dose (MED) was determined. On day 56, the volunteers were exposed to 1.5 MED twice within 10 hrs on a 10x10 cm area on the right buttock from a 1,000 W xenon solar simulator, with an exposure spectrum according to the standards for determining sun protection factors. On days 1, 4 and 10 post-irradiation, suction blister roofs and biopsies were again collected from the right and left buttocks. Results were based on comparisons between exposed and un-exposed areas for each subject, and included immuno-histochemical analysis (scoring) of a number of cellular markers performed double-blind by a single examiner. In addition, epidermal cells (not further characterised) were isolated, and mixed epidermal cell-(allogenic) lymphocyte reactions were performed with lymphocytes from three unrelated allogeneic donors. The Panel notes that no functional studies on the immune response against foreign antigens were provided. The Panel further notes that in the statistical analysis only within-group comparisons were reported, with no statistical comparison between the two groups. The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claim.
One animal study on the effect of L. johnsonii on UV-induced immunosuppression was provided. The Panel considers that evidence provided in animal studies is not sufficient to predict the occurrence of an effect of Lactobacillus johnsonii La1 consumption on protection of the skin from UV-induced damage in humans.
The Panel concludes that a cause and effect relationship has not been established between the consumption of Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and protection of the skin from UV-induced damage.

Warunki i możliwe ograniczenia stosowania oświadczenia

at least 5x109 cfu/day Powder